In the Insulin Resistance Intervention after Stroke (IRIS) trial, performed in non-diabetic but insulin-resistant patients with a history of stroke or transient ischemic attack, pioglitazone was able to lower the risk for recurrent stroke or myocardial infarction compared with placebo therapy [36]. The gene discussed is INS; the disease is Stroke.